Scientists have shown in mice that skin cells re-programmed into brain stem cells, transplanted into the central nervous system, help reduce inflammation and may be able to help repair damage caused by multiple sclerosis (MS).
Our mouse study suggests that using a patient’s reprogrammed cells could provide a route to personalised treatment of chronic inflammatory diseases, including progressive forms of MS
The study, led by researchers at the University of Cambridge, is a step towards developing personalised treatments based on a patient’s own skin cells for diseases of the central nervous system (CNS).
In MS, the body’s own immune system attacks and damages myelin, the protective sheath around nerve fibres, causing disruption to messages sent around the brain and spinal cord. Symptoms are unpredictable and include problems with mobility and balance, pain, and severe fatigue.
Key immune cells involved in causing this damage are macrophages (literally ‘big eaters’), which ordinarily serve to attack and rid the body of unwanted intruders. A particular type of macrophage known as microglia are found throughout the brain and spinal cord – in progressive forms of MS, they attack the CNS, causing chronic inflammation and damage to nerve cells.
Recent advances have raised expectations that diseases of the CNS may be improved by the use of stem cell therapies. Stem cells are the body’s ‘master cells’, which can develop into almost any type of cell within the body. Previous work from the Cambridge team has shown that transplanting neural stem cells (NSCs) – stem cells that are part-way to developing into nerve cells – reduces inflammation and can help the injured CNS heal.
However, even if such a therapy could be developed, it would be hindered by the fact that such NSCs are sourced from embryos and therefore cannot be obtained in large enough quantities. Also, there is a risk that the body will see them as an alien invader, triggering an immune response to destroy them.
A possible solution to this problem would be the use of so-called ‘induced neural stem cells (iNSCs)’ – these cells can be generated by taking an adult’s skin cells and ‘re-programming’ them back to become neural stem cells. As these iNSCs would be the patient’s own, they are less likely to trigger an immune response.
Now, in research published in the journal Cell Stem Cell, researchers at the University of Cambridge have shown that iNSCs may be a viable option to repairing some of the damage caused by MS.
Using mice that had been manipulated to develop MS, the researchers discovered that chronic MS leads to significantly increased levels of succinate, a small metabolite that sends signals to macrophages and microglia, tricking them into causing inflammation, but only in cerebrospinal fluid, not in the peripheral blood.
Transplanting NSCs and iNSCs directly into the cerebrospinal fluid reduces the amount of succinate, reprogramming the macrophages and microglia – in essence, turning ‘bad’ immune cells ‘good’. This leads to a decrease in inflammation and subsequent secondary damage to the brain and spinal cord.
“Our mouse study suggests that using a patient’s reprogrammed cells could provide a route to personalised treatment of chronic inflammatory diseases, including progressive forms of MS,” says Dr Stefano Pluchino, lead author of the study from the Department of Clinical Neurosciences at the University of Cambridge.
“This is particularly promising as these cells should be more readily obtainable than conventional neural stem cells and would not carry the risk of an adverse immune response.”
The research team was led by Dr Pluchino, together with Dr Christian Frezza from the MRC Cancer Unit at the University of Cambridge, and brought together researchers from several university departments.
Dr Luca Peruzzotti-Jametti, the first author of the study and a Wellcome Trust Research Training Fellow, says: “We made this discovery by bringing together researchers from diverse fields including regenerative medicine, cancer, mitochondrial biology, inflammation and stroke and cellular reprogramming. Without this multidisciplinary collaboration, many of these insights would not have been possible.”
The Latest on: Personalised stem cell treatment
via Google News
The Latest on: Personalised stem cell treatment
- Deep-learning tech reveals personal ID of cancer cellson October 15, 2019 at 9:35 pm
Researchers at the Technion-Israel Institute of Technology have now used artificial intelligence and big datato decode the unique signatures of certain cancer cells. The resulting ... boost ...
- Research on cell division provides new clues to how a common cancer treatment workson October 15, 2019 at 6:20 am
Now, Rockefeller scientists present a new way of understanding how Taxol works—and why it may not work in some cancer cells. Their findings might point to new ways of predicting which patients are ...
- Global Personalized Cancer Vaccine Market Opportunity Clinical Innovation Trend Outlook 2026on October 15, 2019 at 2:22 am
They unusually work by enhancing the ability of immune cells to recognize, target and destroy entities that might be harmful ... thus forming the backbone of the global cancer therapy market. This ...
- Tailor-made drug for girl with incurable disease could pave way for customized treatmentson October 14, 2019 at 4:15 pm
This report shows a path to personalized treatments for patients with orphan diseases,' the ... The disorder is caused by waste buildup in the cells, which creates neurodegenerative effects including ...
- NextUp: Tmunity Therapeutics Is Pioneering Personalized Cancer Treatmentson October 14, 2019 at 12:27 pm
The therapy also has potential for treating medulloblastoma, small cell lung cancer, and several other pediatric and adult cancers that express an abundance of the GPC2 protein on their cell surface.
- Individualized treatments for the manyon October 10, 2019 at 2:16 pm
Broadening access to personalized medicines will require scalable and efficient ... The ex vivo expansion of patient-specific therapeutic T cells for adoptive transfer is also a long process. Still, ...
- Mini organs grown from tumour cells can help us choose the best chemoon October 9, 2019 at 11:17 am
To better predict if a treatment will work or not, teams around the world have been working to develop personalised organoids – using clumps of cells biopsied from a person’s tumour. The idea is that ...
- Lab-grown, testosterone-producing cells could help treat hypogonadismon October 9, 2019 at 6:47 am
Researchers at the University of South Carolina have managed to grow human, testosterone-producing cells in the laboratory, a development that could lead to improved treatment of low testosterone ...
- Treatment for 'low T' could someday come from a single skin cellon October 7, 2019 at 3:43 pm
Researchers have successfully grown human, testosterone-producing cells in the lab, paving the way to someday treat low testosterone with personalized replacement cells ... obesity and bone density -- ...
- Treatment for 'low T' could someday come from a single skin cell, research showson October 7, 2019 at 12:06 pm
USC researchers have successfully grown human, testosterone-producing cells in the lab, paving the way to someday treat low testosterone with personalized replacement cells ... Testosterone ...
via Bing News